Cargando…

Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors

BACKGROUND: Axial spondyloarthritis (axSpA) is a potentially disabling inflammatory arthritis of the spine, usually presenting as chronic back pain typically before the age of 45 years. It is often associated with one or more articular features, including synovitis, enthesitis, and dactylitis. It ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Binh, Bui Hai, Trung, Nguyen Ngoc, Hung, Nguyen-Van, Yen, Nguyen-Thi Ngoc, Hoa, Nguyen-Thi Nhu, Hiep, Nguyen Thanh, Duc, Nguyen Minh, Phuong, Le-Thi Bich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AVICENA, d.o.o., Sarajevo 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545927/
https://www.ncbi.nlm.nih.gov/pubmed/37795165
http://dx.doi.org/10.5455/msm.2023.35.222-227
_version_ 1785114768554590208
author Binh, Bui Hai
Trung, Nguyen Ngoc
Hung, Nguyen-Van
Yen, Nguyen-Thi Ngoc
Hoa, Nguyen-Thi Nhu
Hiep, Nguyen Thanh
Duc, Nguyen Minh
Phuong, Le-Thi Bich
author_facet Binh, Bui Hai
Trung, Nguyen Ngoc
Hung, Nguyen-Van
Yen, Nguyen-Thi Ngoc
Hoa, Nguyen-Thi Nhu
Hiep, Nguyen Thanh
Duc, Nguyen Minh
Phuong, Le-Thi Bich
author_sort Binh, Bui Hai
collection PubMed
description BACKGROUND: Axial spondyloarthritis (axSpA) is a potentially disabling inflammatory arthritis of the spine, usually presenting as chronic back pain typically before the age of 45 years. It is often associated with one or more articular features, including synovitis, enthesitis, and dactylitis. It may also be associated with several non-articular features; these include uveitis, psoriasis, and inflammatory bowel diseases1. OBJECTIVE: The aim of this article is to describe the status of using biological drugs and some related factors in treating ankylosing spondylitis in Vietnam. METHODS: A joint prospective and retrospective cross-sectional descriptive study was conducted on 161 ankylosing spondylitis patients treated with biological drugs at the Centre for Rheumatology between January 2018 and July 2021. Data were collected at the first dose and after 3, 6, 12, 24, and 36 months, including general characteristics, clinical and para-clinical features, drug use status, and related factors. RESULTS: Of the 161 patients, 86.3% were male, with a mean age of 31.1 ± 11.6 years and a mean disease duration of 7.6 ± 6.6 years. Most patients were started on biologics at stage II (46.6%) or III (28.6%). Moreover, 68.9% had active disease based on the Bath Ankylosing Spondylitis Disease Activity Index. The most commonly prescribed first-line therapy was anti-tumor necrosis factor (69.6%), with infliximab the most frequently prescribed drug (44.7%). The rate of biological drug treatment decreased gradually from 100% at the start to 77% after one year and 39.1% after three years. Moreover, 74% of patients changed drugs due to non-response, and 50% discontinued treatment for economic reasons. Age was associated with treatment adherence, and drug change rates were higher in female patients and patients with active disease. Age was significantly associated with drug discontinuation (p < 0.05). CONCLUSION: Infliximab was the most commonly prescribed first-line drug. The rate of biological therapy gradually decreased after three years. Most patients changed drugs due to non-response, and many discontinued the drugs for economic reasons. Among the individual and clinical factors, age was associated with treatment adherence.
format Online
Article
Text
id pubmed-10545927
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AVICENA, d.o.o., Sarajevo
record_format MEDLINE/PubMed
spelling pubmed-105459272023-10-04 Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors Binh, Bui Hai Trung, Nguyen Ngoc Hung, Nguyen-Van Yen, Nguyen-Thi Ngoc Hoa, Nguyen-Thi Nhu Hiep, Nguyen Thanh Duc, Nguyen Minh Phuong, Le-Thi Bich Mater Sociomed Original Paper BACKGROUND: Axial spondyloarthritis (axSpA) is a potentially disabling inflammatory arthritis of the spine, usually presenting as chronic back pain typically before the age of 45 years. It is often associated with one or more articular features, including synovitis, enthesitis, and dactylitis. It may also be associated with several non-articular features; these include uveitis, psoriasis, and inflammatory bowel diseases1. OBJECTIVE: The aim of this article is to describe the status of using biological drugs and some related factors in treating ankylosing spondylitis in Vietnam. METHODS: A joint prospective and retrospective cross-sectional descriptive study was conducted on 161 ankylosing spondylitis patients treated with biological drugs at the Centre for Rheumatology between January 2018 and July 2021. Data were collected at the first dose and after 3, 6, 12, 24, and 36 months, including general characteristics, clinical and para-clinical features, drug use status, and related factors. RESULTS: Of the 161 patients, 86.3% were male, with a mean age of 31.1 ± 11.6 years and a mean disease duration of 7.6 ± 6.6 years. Most patients were started on biologics at stage II (46.6%) or III (28.6%). Moreover, 68.9% had active disease based on the Bath Ankylosing Spondylitis Disease Activity Index. The most commonly prescribed first-line therapy was anti-tumor necrosis factor (69.6%), with infliximab the most frequently prescribed drug (44.7%). The rate of biological drug treatment decreased gradually from 100% at the start to 77% after one year and 39.1% after three years. Moreover, 74% of patients changed drugs due to non-response, and 50% discontinued treatment for economic reasons. Age was associated with treatment adherence, and drug change rates were higher in female patients and patients with active disease. Age was significantly associated with drug discontinuation (p < 0.05). CONCLUSION: Infliximab was the most commonly prescribed first-line drug. The rate of biological therapy gradually decreased after three years. Most patients changed drugs due to non-response, and many discontinued the drugs for economic reasons. Among the individual and clinical factors, age was associated with treatment adherence. AVICENA, d.o.o., Sarajevo 2023-09 /pmc/articles/PMC10545927/ /pubmed/37795165 http://dx.doi.org/10.5455/msm.2023.35.222-227 Text en © 2023 Bui Hai Binh, Nguyen Ngoc Trung, Nguyen-Van Hung, Nguyen-Thi Ngoc Yen, Nguyen-Thi Nhu Hoa, Nguyen Thanh Hiep, Nguyen Minh Duc, Le-Thi Bich Phuong https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Binh, Bui Hai
Trung, Nguyen Ngoc
Hung, Nguyen-Van
Yen, Nguyen-Thi Ngoc
Hoa, Nguyen-Thi Nhu
Hiep, Nguyen Thanh
Duc, Nguyen Minh
Phuong, Le-Thi Bich
Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors
title Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors
title_full Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors
title_fullStr Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors
title_full_unstemmed Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors
title_short Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors
title_sort current status of biological treatment in ankylosing spondylitis patients and some related factors
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545927/
https://www.ncbi.nlm.nih.gov/pubmed/37795165
http://dx.doi.org/10.5455/msm.2023.35.222-227
work_keys_str_mv AT binhbuihai currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT trungnguyenngoc currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT hungnguyenvan currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT yennguyenthingoc currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT hoanguyenthinhu currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT hiepnguyenthanh currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT ducnguyenminh currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors
AT phuonglethibich currentstatusofbiologicaltreatmentinankylosingspondylitispatientsandsomerelatedfactors